🔎 Trials Near Me

Beranda › Lupus › Oklahoma

Uji klinis Lupus di Oklahoma

8 studi untuk Lupus mencari peserta di lokasi di Oklahoma.

Kota di Oklahoma

Teks studi resmi (Bahasa Inggris)

A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus

  • Sl0044 50262, Oklahoma City
Menerima pesertaFase 3
Usia 16 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06617325

A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)

  • Oklahoma Medical Research Foundation, Oklahoma City
Menerima pesertaFase 2
Usia 18 hingga 74 · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT07409181

A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus

  • Research Site, Oklahoma City
  • Research Site, Oklahoma City
Menerima pesertaFase 3
Usia 18 hingga 70 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07430306

A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants

  • Oklahoma Medical Research Foundation, Oklahoma City
Menerima pesertaStudi observasional
Usia 16 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT07175285

Effects of Stopping Hydroxychloroquine in Elderly Lupus Disease

  • Oklahoma Medical Research Foundation, Oklahoma City
Menerima pesertaFase 3
Usia 55 ke atas · Semua jenis kelamin · Diperbarui 20 Agu 2026 · NCT05799378

A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease

  • University of Oklahoma, Oklahoma City
Menerima pesertaFase 1
Usia 12 hingga 70 · Semua jenis kelamin · Diperbarui 22 Mei 2026 · NCT06308978

Safety of the Herpes Zoster Subunit Vaccine in Lupus

  • Oklahoma Medical Research Foundation, Oklahoma City
Menerima pesertaFase 4
Usia 18 hingga 90 · Semua jenis kelamin · Diperbarui 26 Des 2025 · NCT05559671

Dari ClinicalTrials.gov, data diambil 3 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.